"Estrogen" is the headline word, but the body actually makes three: estradiol (E2, the dominant one in your reproductive years), estrone (E1, the one that takes over after menopause), and estriol (E3, mostly seen in pregnancy). When perimenopause and MHT pages say "estrogen", they almost always mean estradiol — and the modern prescribing conversation is increasingly about getting transdermal estradiol (a patch, gel, or spray) to a steady level, rather than older oral conjugated forms.
Estrogen in three answers.
What it does
Estrogen does a lot more than the period. It supports bone density, cardiovascular tone, the lining of the vagina and bladder, the temperature regulator in the hypothalamus, mood, sleep architecture, and a meaningful chunk of executive function and verbal memory. It's a quietly load-bearing hormone for a lot of systems that don't sound 'reproductive' on the label.
What changes in perimenopause
In perimenopause, estrogen doesn't drift gently downward — it swings. High peaks, lower troughs, increasingly erratic from one cycle to the next. By the time periods stop for good (the definition of menopause is twelve months without one), estradiol is low and stays low, although the adrenal glands and fat tissue continue to make small amounts of weaker estrogens.
Where you'll feel it
Hot flashes and night sweats. Sleep that fragments around 3 a.m. Brain fog and word-finding gaps. Joint pain that wasn't there before. Vaginal dryness, urinary urgency, recurrent UTIs. The 'I don't recognize my body' feeling that's hard to point at one symptom.
Noticing, assessment and follow-up
Your next steps
For yourself, or for your next appointment. These are questions and things to notice, not a diagnosis or a treatment plan.
What can I notice?
- Note hot flashes, night sweats, sleep, vaginal or urinary discomfort and any bleeding changes, plus what you want to feel easier. Record the start or change date if you're using treatment.
- Tell your doctor or specialist about hormonal contraception, surgery and gender-affirming hormones. These can change how symptoms, periods and test results are interpreted.
Could a test help?
- NICE usually identifies menopause clinically in otherwise healthy people aged 45 or older with typical symptoms, without an estradiol test. FSH may help at 40–45 or when menopause is suspected under 40; younger ages and unusual symptoms need an individual assessment. Hormonal contraception can make FSH unsuitable.
- Ask whether a test is investigating another possible cause of your symptom rather than measuring menopause. A single estrogen result doesn't decide which treatment you need.
What happens next?
- Discuss systemic MHT for relevant symptoms separately from low-dose vaginal estrogen for local symptoms. If you have a uterus and use systemic estrogen, ask about protection of the uterine lining with a progestogen.
- NICE recommends a clinical treatment review at 3 months, then annually, sooner if it isn't working or side effects develop. Ask how you'll receive any results, who'll review them and what to do before the next appointment. This isn't a schedule for routine hormone blood panels.
When shouldn't I wait?
- Ask what's expected with your particular regimen. NICE says unscheduled bleeding can be common in the first 6 months of systemic MHT, or within 3 months of changing the dose or preparation. Report bleeding beyond these windows promptly. Heavy or prolonged bleeding needs earlier assessment, whatever the timing; these windows aren't permission to ignore it.
- Seek urgent help for heavy bleeding with dizziness, fainting or breathlessness. New chest pain, sudden breathlessness or stroke-like symptoms need emergency help.
Sources for these next steps
What to say out loud.
Menopausal hormone therapy (MHT), often called HRT, usually means systemic estrogen, with a progestogen added if you have a uterus. Low-dose local vaginal estrogen is a separate treatment. 'Body-identical' or 'bioidentical' transdermal estradiol is the most-prescribed form in the UK and increasingly in Canada and Australia.
Pick the part you came for.
4 sections. Open one, skip the rest — nothing here depends on reading in order.
The bone story
Why bone density falls fastest in the first five years
Estrogen tells the bone-resorbing cells (osteoclasts) to slow down. When estradiol drops at menopause, osteoclasts speed up and start removing bone faster than the bone-building cells (osteoblasts) can replace it. Bone loss is often fastest in the first 5 years after the final period — cited at roughly 1 to 2 per cent per year of trabecular bone in cohort studies, more if periods stopped before 45.
Read the rest
This is why MHT started within 10 years of the final period reliably preserves bone density and reduces hip and vertebral fractures. It's also why a baseline DEXA scan is reasonable for anyone with early menopause, low body weight, eating disorder history, long steroid use, or a family history of hip fracture.
The brain story
What 'menopause brain' actually is
Estrogen receptors are dense in the hippocampus, prefrontal cortex, and amygdala — the regions that handle verbal memory, executive function and emotional regulation. As estradiol falls, glucose uptake in some of these regions measurably drops on PET imaging. That's the biological basis for the word-finding pauses, the lost-thread feeling, the slower processing in meetings.
Read the rest
For most people, the cognitive changes ease 1 to 2 years after the final period as the brain re-equilibrates. For a smaller group they don't, and for people with strong family histories of dementia the long-game question of MHT and brain health is genuinely unsettled — there's signal that early-window MHT may be neutral-to-protective for Alzheimer's risk, and signal that late-start MHT may be the opposite. Worth a frank conversation with a menopause-trained doctor, not a forum.
The vagina, bladder and pelvic floor
GSM is its own conversation, and it never resolves on its own
Genitourinary syndrome of menopause (GSM) is the umbrella term for vaginal dryness, painful sex, urinary urgency, post-coital UTIs, and the thinning of vulvar skin. Up to 80 per cent of postmenopausal women develop it, and unlike hot flashes it doesn't pass with time — it gets steadily worse without treatment.
Read the rest
Topical (vaginal) estrogen — cream, ring, or pessary — is the standard of care, with very low systemic absorption and a reassuring safety profile even for many people who can't take systemic MHT. It's consistently rated one of the highest-impact, lowest-risk treatments in menopause care and is consistently under-prescribed.
The breast-cancer signal, in real numbers
What the WHI actually showed, and what came after
The 2002 Women's Health Initiative headline — 'a 26 per cent increase in breast cancer risk on combined HRT' — was a relative risk on conjugated equine estrogen plus medroxyprogesterone acetate (MPA), in women with an average age of 63. The absolute number was about 8 extra cases per 10 000 women per year — smaller than the risk attributed to drinking two glasses of wine a night or being five units of BMI heavier.
Read the rest
Estrogen-only MHT (for women without a uterus) didn't increase breast cancer risk in WHI and may have lowered it slightly. More recent observational data suggest that body-identical micronised progesterone carries a smaller breast signal than older synthetic progestins, particularly in the first 5 years of use. The honest sentence is 'small absolute increase, mostly tied to specific synthetic progestins, mostly after several years of use', not 'HRT causes breast cancer'.
10 sources behind this pagePrimary papers and guidelines only. Each card opens the original.
Up to 80 per cent of postmenopausal women have hot flashes; the median duration is 7.4 years.
Avis et al · Study of Women's Health Across the Nation, n=1449
The largest cohort of midlife women followed prospectively across the menopause transition. The 7.4-year median is the number that quietly retired the 'hot flashes are short-lived' assumption.
Read the sourceMHT started within 10 years of the final period preserves bone mineral density and reduces hip and vertebral fractures.
The reference position statement cited internationally. The bone-protective effect is one of the most consistent findings in the entire MHT literature.
Read the sourceTransdermal estradiol doesn't raise venous thromboembolism risk; oral estrogen modestly does.
Vinogradova et al · UK primary-care nested case-control, n>80 000
Why patches and gels are now first-line in the UK and why route matters as much as molecule.
Read the sourceVaginal (low-dose local) estrogen is effective for GSM and is reassuring on safety, including in many breast-cancer survivors after specialist discussion.
The single most under-prescribed high-impact treatment in menopause care. Worth re-raising at every appointment.
Read the sourceWHI: oral CEE + MPA produced about 8 extra cases of breast cancer per 10 000 women per year; estrogen-only didn't increase breast cancer risk and possibly lowered it.
Writing Group for the Women's Health Initiative
The original 2002 paper, in context. The relative-risk headline is what stuck; the absolute numbers and the estrogen-only arm are the parts that kept getting lost.
Read the sourceBody-identical micronised progesterone appears to carry a smaller breast cancer signal than older synthetic progestins, particularly in the first 5 years.
Stute et al
Why most modern UK and European prescribing pairs transdermal estradiol with oral micronised progesterone rather than the older synthetic progestins.
Read the sourcePerimenopause is best understood as a neurological transition state — estrogen withdrawal in brain regions dense with estrogen receptors (hippocampus, prefrontal cortex, hypothalamus) drives the sleep, mood and cognitive symptoms, not 'hormonal moodiness'.
Brinton et al
The foundational paper for treating perimenopause symptoms as a brain event with measurable mechanisms, rather than a personality drift. Useful when an appointment frames brain fog or mood as 'just stress'.
Read the sourceSex steroids shape the female brain across the lifespan — estrogen withdrawal and progesterone-related changes influence risk of depression and Alzheimer's disease, with the menopause transition as a key window.
Barth et al
A wide-ranging review that ties together the brain-estrogen story from puberty through menopause, with direct relevance to depression and dementia risk.
Read the sourceThe menopause transition itself accelerates cardiovascular risk — visceral fat, lipid profile and arterial stiffness all shift adversely across the FMP, independent of chronological ageing.
El Khoudary et al · SWAN-derived AHA statement
The clearest synthesis of the SWAN cardiovascular trajectory data. The reason cardiometabolic screening at the perimenopause-to-postmenopause boundary is worth pushing for, even when individual numbers still look 'fine'.
Read the sourceIn women with vasomotor symptoms, hormone therapy didn't increase cardiovascular disease risk and appeared to lower it when started in perimenopause or early postmenopause; cardiovascular risk rose only in women aged 70 and older.
VCU and Pittsburgh · secondary analysis of 2 WHI trials, n=27,347
The first US analysis to look at cardiovascular outcomes from HT specifically in women with hot flashes and night sweats. Refines the timing hypothesis: the women who actually need HT for symptoms are the ones for whom the cardiovascular signal looks favourable, and the risk concentrates in the over-70 group who were never the typical symptomatic patient.
Read the sourceRelated